Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-471 (Vepdegestrant) Alone and with Palbociclib in ER+/HER2- Advanced Breast Cancer
NCT04072952Phase 2Completed
- Sponsor
- Arvinas
- Start
- Sep 2019
- Primary completion
- Sep 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of vepdegestrant in breast cancer, sponsored by Arvinas. Started Sep 2019; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04072952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072952.